GFM
TVTX icon

GF Fund Management’s Travere Therapeutics TVTX Stock Holding History

GF Fund Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
1,955
-54
-3% -$2.39K ﹤0.01% 322
2026
Q1 		$59.7K Buy
2,009
+252
+14% +$7.53K ﹤0.01% 379
2025
Q4 		$67.1K Sell
1,757
-161
-8% -$5.24K ﹤0.01% 381
2025
Q3 		$45.8K Sell
1,918
-280
-13% -$5.26K ﹤0.01% 401
2025
Q2 		$32.5K Hold
2,198
– – ﹤0.01% 450
2025
Q1 		$39.4K Buy
2,198
+395
+22% +$8.02K ﹤0.01% 442
2024
Q4 		$31.4K Buy
+1,803
New +$31.9K ﹤0.01% 431

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

GF Fund Management's TVTX Position: Q2 2026 in Review

GF Fund Management reduced its Travere Therapeutics (TVTX) stake by 2.7% in Q2 2026, selling an estimated $2.39K and leaving 1,955 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #322.

GF Fund Management first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • GF Fund Management held 1,955 shares of Travere Therapeutics worth $111K as of Q2 2026.
  • GF Fund Management sold 54 Travere Therapeutics shares in Q2 2026, an estimated $2.39K.
  • Travere Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #322 holding.
  • GF Fund Management first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.